Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266983 | 0.90 | MEN1 (0.48) | SMN1; SMN2MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL11101654 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2AALDH1A1LMNAGAA | |
| SCHEMBL13875066 | 0.83 | HTT (0.44) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL15616940 | 0.83 | MEN1 (0.36) | SMN1; SMN2MEN1KMT2AKDM4EMTNR1A | |
| SCHEMBL18839657 | 0.81 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL23028661 | 0.81 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL15312533 | 0.80 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL19002630 | 0.79 | POLB (0.40) | SMN1; SMN2KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL19059340 | 0.78 | LMNA (0.44) | SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL23028662 | 0.78 | GAA (0.33) | TSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | SMN1; SMN2 4331/4885MEN1 4080/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.